Insmed Inc. (INSM)
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He's Buying Now.
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing.
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
Insmed Incorporated (INSM) Presents at Jefferies London Healthcare Conference 2025 Transcript
Insmed Incorporated ( INSM ) Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM EST Company Participants William Lewis - President, CEO & Chairman Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division Good morning, everyone. Thanks for joining the session -- fireside session was Insmed and my name is Clara Dong, one of the biotech analysts here.
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.
Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript
Insmed Incorporated ( INSM ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Bryan Dunn - Vice President of Investor Relations William Lewis - President, CEO & Chairman Roger Adsett - Chief Operating Officer Sara Bonstein - Chief Financial Officer Martina Flammer - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Ritu Baral - TD Cowen, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jason Zemansky - BofA Securities, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Yuxi Dong - Jefferies LLC, Research Division Ashwani Verma - UBS Investment Bank, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Leonid Timashev - RBC Capital Markets, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Maxwell Skor - Morgan Stanley, Research Division Samuel Lee - Mizuho Securities USA LLC, Research Division Brandon Frith - Wolfe Research, LLC Presentation Operator Thank you for standing by.
Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.75 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.27 per share a year ago.
Gear Up for Insmed (INSM) Q3 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Insmed (INSM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock
Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript
Insmed Incorporated (NASDAQ:INSM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Bryan Dunn - Vice President of Investor Relations Martina Flammer - Chief Medical Officer Roger Adsett - Chief Operating Officer Sara M. Bonstein - Chief Financial Officer William H.
Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
